ライフサイエンスコーパス: cell immunity

1 gnancy is associated with recovery of CD4+ T cell immunity.

2 ges of tumor inception to subvert adaptive T cell immunity.

3 tion of human DCs compromises WNV-specific T cell immunity.

4 icant impact on HPV-specific CD8+ and CD4+ T cell immunity.

5 an innate link between viral infection and B cell immunity.

6 s are an essential component of long-lived T cell immunity.

7 ed partly on induction of sustainable host T-cell immunity.

8 subsets that likely compromise anti-tumor T cell immunity.

9 ubjects has a significant effect on T- and B-cell immunity.

10 okine family involved in the regulation of B-cell immunity.

11 s in nanoparticles for inducing anticancer T-cell immunity.

12 ir JAK/STAT pathways play pivotal roles in T cell immunity.

13 s but did not explain the defect in CD8(+) T cell immunity.

14 critical for the generation of protective T cell immunity.

15 eous and PD-L1-blockade-mediated antitumor T cell immunity.

16 d "atypical" SCID show reduced, not absent T-cell immunity.

17 ction of IL-1beta, and defective antiviral T cell immunity.

18 r sterols and oxysterols in macrophage and T-cell immunity.

19 review examines the effects of MS DMTs on B-cell immunity.

20 ire is fundamental to our understanding of B-cell immunity.

21 and atg5 in regulating TLR signalling and B-cell immunity.

22 en-presenting cells to stimulate antitumor T-cell immunity.

23 the generation of an optimal effector CD8 T cell immunity.

24 epsis might facilitate the recovery of CD8 T cell immunity.

25 as associated with enhanced virus-specific T-cell immunity.

26 lay an important role in the regulation of B-cell immunity.

27 nd inhibits formation of pathogen-specific T cell immunity.

28 nction of FcgammaRIIB in regulating CD8(+) T cell immunity.

29 TP on innate proinflammatory responses and T-cell immunity.

30 , suggesting interference of carriage with T-cell immunity.

31 fied E2A and E2-2 as central regulators of B cell immunity.

32 nism involving the inhibition of antitumor T-cell immunity.

33 class II expression, suggesting a role in T cell immunity.

34 fiers to explore the long-term dynamics of T cell immunity.

35 immunogenicity for inducing antibodies and T cell immunity.

36 development of vaccines that evoke optimal T cell immunity.

37 d qualitatively altered YF-specific CD4(+) T cell immunity.

38 ing as a viable approach to augment CD8(+) T-cell immunity.

39 r (NK) cells, macrophage polarization, and T-cell immunity.

40 udies unveil an essential role of Gpx4 for T cell immunity.

41 pecific subsets of dendritic cells and CD8 T cell immunity.

42 y bowel disease-all with severely impaired T-cell immunity.

43 ter with a conditioning regimen to restore B-cell immunity.

44 inadequacy to evade HLA-A*02:01-restricted T-cell immunity.

45 t peptide is virtually unable to stimulate T cell immunity.

46 01 molecule, and play an important role in T-cell immunity.

47 immunoregulatory cytokine IL-10 suppresses T-cell immunity.

48 characterized by their ability to inhibit T cell immunity.

49 tissue in part by evading antiviral CD8(+) T cell immunity.

50 of Th17 cells to preserve an effective HIV T-cell immunity.

51 survival by inducing robust tumor-specific T-cell immunity.

52 verlapping and yet distinct mucosal and DC/T cell immunity.

53 re considered to play little or no role in T cell immunity.

54 l strategy to harness endogenous antitumor T-cell immunity.

55 broad spectrum of biological processes of T cell immunity.

56 sm with superior long-term recovery of CD4 T-cell immunity.

57 tion immunotherapies that can fully engage T-cell immunity.

58 ed to low expression of STAT5 and impaired T cell immunity.

59 t endogenous GCs both promote and suppress T cell immunity.

60 IL-2 production to facilitate optimal CD8 T cell immunity.

61 Adaptive evolution is a key feature of T cell immunity.

62 thogenesis, but few studies have evaluated T cell immunity.

63 tment, which is crucial for suppression of T-cell immunity.

64 ced on activated T cells, is important for T-cell immunity.

65 al persistence associates with compromised T cell immunity.

66 n of antigen-presenting cells that promote T-cell immunity.

67 ochemical information and are critical for T-cell immunity.

68 lar source, and timing of Notch signals in T cell immunity.

69 ed to strong cross-priming and durable CD8 T cell immunity.

70 herapy associated with enhanced anti-tumor T cell immunity.

71 ckpoint that is crucial for the control of T cell immunity.

72 systemic poly-functional CD4(+) and CD8(+) T cell immunity.

73 ake deficiency severely impaired antitumor T cell immunity.

74 ion, and ablation of FGL1 in mice promotes T cell immunity.

75 and exploit PD-L1/PD-1 signaling to evade T cell immunity.

76 e rather than compromise protective CD8(+) T cell immunity.

77 HR) in TAMs to modulate their function and T cell immunity.

78 for the upregulation of genes involved in T-cell immunity.

79 facilitates the emergence of potent CD8(+) T-cell immunity able to durably suppress virus replication

80 n single lymphoma nodes, mediated systemic T-cell immunity accompanied by regression of disseminated

81 Quantifying CMV-specific T-cell immunity after HSCT can identify participants at in

82 help to further characterize MuV-specific T-cell immunity after natural MuV infection or vaccination

83 ween DC dysfunction and impairments in CD8 T cell immunity after sepsis by directly targeting Ag to D

84 al strategies for generating heterogeneous T-cell immunity against cancer, with the appropriate balan

85 Here we show that T cell immunity against commensal papillomaviruses suppres

86 Our data demonstrate that IgG1(+) B-cell immunity against food allergens in epicutaneous sen

87 We previously described CD4(+) T-cell immunity against HBsAg and polymerase in chimpanzee

88 h nodes to program DCs to direct effective T cell immunity against IAV.

89 Induction of B-cell immunity against infection depends on the initiatio

90 g cell motility are essential for adaptive T-cell immunity against infectious pathogens and cancers.

91 evidences support a critical role of CD8+ T cell immunity against influenza.

92 evidence supports a critical role of CD8+ T-cell immunity against influenza.

93 that dendritic cells help CD4(+) T helper 1 cell immunity against malaria through PD-L2's competitio

94 pensable for establishing effective CD4(+) T cell immunity against malaria, because it not only inhib

95 T-cell immunity against stem-cell antigen SOX2 and preserv

96 D-L1 expression in tumour cells to enhance T-cell immunity against the tumours.

97 Normal VZV-specific T-cell immunity and antibody response were detected.

98 ells improves spontaneous antitumor CD8(+) T cell immunity and boosts the efficacy of T cell-based im

99 ether, and how, ferroptosis is involved in T cell immunity and cancer immunotherapy.

100 IL-7 is a key factor in T cell immunity and common variants at IL7R, encoding its

101 ss of GCIPL is associated with intrathecal B-cell immunity and constitutes an independent risk factor

102 recently been shown to correlate with anti T-cell immunity and efficacy of checkpoint inhibitor thera

103 the current understanding of HIV-specific T-cell immunity and identify cellular immune responses and

104 e was partially mediated by tumor-specific T cell immunity and immunological memory.

105 phase augmented DC vaccine-induced CD8(+) T-cell immunity and improved antitumor efficacy, suggestin

106 acute stages of sepsis develop compromised T cell immunity and increased susceptibility to infection.

107 tween amino acid metabolism, and effective T cell immunity and its relevance in cancer therapies.

108 to be a crucial component of EBV-specific T cell immunity and more generally for the immune surveill

109 key discoveries in the area of flavivirus T cell immunity and postulate on how these findings can in

110 pressing macrophages that inhibited CD8(+) T cell immunity and promoted CD4(+)Foxp3(+) Treg cell expa

111 he complex regulatory mechanisms governing T cell immunity and regulation of a critical T cell checkp

112 aemia, which leads to the establishment of T-cell immunity and resultant long-term infection control.

113 there is a correlate of protection between T cell immunity and Shingrix efficacy.

114 nses results in significant alterations in T cell immunity and subsequent disease outcome upon reexpo

115 ib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockade

116 zed antigen-presenting cells that initiate T cell immunity and tolerance.

117 are critical in the maintenance of normal T cell immunity and tolerance.

118 Thus, both T cell immunity and trypanocidal pharmacotherapy suppress

119 allele predicted resurgent virus-specific T-cell immunity and viral control at 3-mo postpartum (P =

120 vectors failed to reconstitute B-cell and NK-cell immunity and was complicated by vector-related leuk

121 cations in the investigations on cancer stem cells, immunity and immune modulators, applications with

122 ute infectious agents induce strong CD8(+) T cell immunity, and are thought to therefore represent a

123 9 receptor, a regulator of Th17/regulatory T cell immunity, and atherosclerosis development in animal

124 ential of MDSC, triggered antitumor CD8(+) T-cell immunity, and boosted the efficacy of T-cell immuno

125 cts the spread of virus infection, optimal B cell immunity, and disease pathogenesis.

126 for FcgammaRIIB-mediated control of CD8(+) T cell immunity, and instead, the immunosuppressive cytoki

127 ominant mechanism for regionalizing CD4(+) T cell immunity, and location enforces shared transcriptio

128 le-exome sequencing (WES), analyses of VZV T-cell immunity, and pathogen recognition receptor functio

129 ve Th17 polarization and influence mucosal T-cell immunity, and suggest that host pathways to handle

130 viral load, the assessment of CMV-specific T-cell immunity, and the molecular assessment of resistanc

131 contributes to the observed defects in CD8 T cell immunity, and therapeutic approaches designed to im

132 e tumor microenvironment controls TAMs and T cell immunity are not completely understood.

133 and the resultant neoantigen landscape on T cell immunity are poorly understood.

134 protective and pathogenic roles of GITR in T cell immunity are well characterized, the role of GITR i

135 The study of T cell immunity at barrier surfaces has largely focused on

136 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 12 months after

137 se among those infected, but the impact of T-cell immunity at the population level is unknown.

138 due to cross-reactive humoral immunity and T cell immunity between common coronaviruses and SARS-CoV-

139 ess can have long-term consequences on CD8 T cell immunity by altering HPA axis activity.

140 Reactivation of T cell immunity by PD-1/PD-L1 immune checkpoint blockade h

141 Our results show that HIV-1-specific T-cell immunity can be detected in exposed but uninfected

142 Because T-cell immunity contributes to the control of many viral p

143 to successful and sustained restoration of T-cell immunity correlated with virologic response and pro

144 s from HPV-16 E6/E7 for which induction of T-cell immunity correlates with disease-free survival in p

145 The fidelity of T cell immunity depends greatly on coupling T cell recepto

146 ) mice were deficient in generating CD8(+) T-cell immunity despite normal clonal expansion, likely du

147 T cell immunity directed against tumor-encoded amino acid

148 ng imply that exosomes function to promote T cell immunity during a bacterial infection and are an im

149 Thus, maternal CD4(+) T-cell immunity during primary rhCMV infection is importan

150 undamental role in the induction of CD8(+) T cell immunity during viral, intracellular bacterial, and

151 endritic cells, preeminent inducers of CD8 T cell immunity; elicit Th1-promoting inflammation; and la

152 tions about the establishment of effective B cell immunity elicited by vaccination, not just against

153 cytogenes (which induces CD4(+) and CD8(+) T-cell immunity) engineered to express Kras(G12D) (LM-Kras

154 noviral vectored vaccines fails to restore T-cell immunity except where there is genetic mismatch bet

155 cident with development of strain-specific T-cell immunity followed by emergence of cross-reactive vi

156 test to identify recovery of CMV-specific T-cell immunity following hematopoietic stem cell transpla

157 e longitudinal development of the adaptive T cell immunity following immunization with Ag is identifi

158 have been a central methodology to measure T cell immunity for many years.

159 great promise to produce antigen-specific T cell immunity for personalized therapy of cancer.

160 importance of functional PMN, T-cell, and NK-cell immunity for the outcome of IA.

161 Thus, B-cell immunity frequently targets cryptotopes on CMV but

162 Thus, CD8(+) T cell immunity generated during primary DENV infection ca

163 T-cell immunity has been linked to the exceptional outcome

164 Restoration of antigen-specific T cell immunity has the potential to clear persistent vira

165 dies (mAbs) able to reinvigorate antitumor T-cell immunity have heralded a paradigm shift in cancer t

166 metabolic regulators controlling antitumor T cell immunity have just begun to be unveiled.

167 ritic cells (cDC1s) for inducing antitumor T-cell immunity; however, strategies to maximize cDC1 enga

168 rrent helminth infection potently inhibits T cell immunity; however, whether helminthes prevent T cel

169 prospectively analyzed antigen-specific B/T-cell immunity, immune composition of the tumor microenvi

170 ssociated tissue in part by evading CD8(+) T cell immunity.IMPORTANCE CHIKV is a reemerging mosquito-

171 tion to compromise priming of WNV-specific T cell immunity.IMPORTANCE West Nile virus (WNV) is an enc

172 mportant studies on the function of T- and B-cell immunity in atherosclerosis and their manipulation

173 f these DC subsets to boost tumor-reactive T cell immunity in cancer patients.

174 e results suggest the critical role of CD4 T cell immunity in controlling varicella virus latency.

175 ctivation suggests a critical role for CD4 T cell immunity in controlling varicella virus latency.IMP

176 y thus be beneficial for optimizing CD8(+) T cell immunity in COVID-19.

177 there has been debate about centrality of T cell immunity in defense, these observations support a r

178 understanding the correlates of protective T cell immunity in HIV infection, the optimal approach to

179 a, due to their ability to potently induce T cell immunity in humans.

180 therefore a novel functional component of T-cell immunity in latent TB and potential correlate of pr

181 DNA sequencing, and assessed CMV-specific T-cell immunity in LTRs at high risk for CMV events, using

182 ections support the clinical importance of T-cell immunity in mediating protective antiviral effects.

183 class II heterodimers and stimulate strong T cell immunity in mice and humans.

184 fine antigenic epitopes determining CD8(+) T cell immunity in murine models of ZIKV infection.

185 lpha therapy fails to boost virus-specific T-cell immunity in patients with chronic hepatitis B virus

186 This investigation of virus-specific T-cell immunity in patients with HDV infection, the larges

187 However, spontaneous antitumor CD8+ T cell immunity in peripheral blood and tumors was restric

188 isplay diminished capacity for controlling T cell immunity in prostate inflammation and cancer models

189 To assess the role of CD4 T cell immunity in reactivation, monkeys were treated with

190 tributing factor leading to diminished CD8 T cell immunity in septic hosts.

191 erest to understand if there is a role for T cell immunity in the differential clinical outcome and i

192 for vaccines and/or therapies that require T cell immunity in the lung.

193 We also report pre-existing human CD8+T cell immunity in the majority of healthy individuals scr

194 (TSLPR), yet a direct role for TSLP in CD8 T cell immunity in the mucosa has not been described.

195 n of TSLP levels may promote long-term CD8 T cell immunity in the mucosa when other prosurvival signa

196 thionine metabolism, histone patterns, and T cell immunity in the tumour microenvironment.

197 BACKGROUNDImpaired T cell immunity in transplant recipients is associated wit

198 lls, and this was accompanied by increased T cell immunity in tumour-bearing mice and patients with c

199 tor and the cytokine IL-2, but its role in T-cell immunity in vivo has not been explored.

200 rimentation to better understand antiviral T-cell immunity in vivo Limiting factors in ACT experiment

201 be of significant importance in regulating T-cell immunity in vivo.

202 eficiencies are marked by inborn errors of T-cell immunity in which the T cells that are present are

203 gies, the therapeutic goal is to re-ignite T-cell immunity, in order to eradicate tumors.

204 e we discuss new approaches to probe human T cell immunity, including novel sampling, that indicate a

205 Identification of positive regulators of T-cell immunity induced during autoimmune diseases is crit

206 he efficient induction of stable antiviral T cell immunity irrespective of the nature of the antigeni

207 Generating effective and durable T cell immunity is a critical prerequisite for vaccination

208 s (IAVs), where the recall of IAV-specific T cell immunity is able to protect against serologically d

209 Reconstitution of T cell immunity is absolutely critical for the effective c

210 Induction of proinflammatory T cell immunity is augmented by innate dendritic cell (DC)

211 ticular, IFN-gamma-polarized cytotoxic CD8 T cell immunity is considered optimal for protective immun

212 T-cell immunity is critical for control of CMV infection,

213 T cell immunity is essential for the control of cytomegalo

214 minimal thresholds for effective antiviral T cell immunity is important for clinical decisions in imm

215 tion against reinfection and that adaptive T cell immunity is important for viral clearance.

216 tment for malaria and other diseases where T cell immunity is ineffective or short-lived due to PD-1-

217 T cell immunity is often defined in terms of memory lympho

218 Optimal CD8 T cell immunity is orchestrated by signaling events initia

219 ery of IL-1beta to determine that adaptive T cell immunity is required for airway remodeling because

220 An important question is whether T-cell immunity is sufficiently strong to drive influenza

221 Thus, eliciting robust CD8 T-cell immunity is the basis for many vaccines under devel

222 f IFN-gamma in tuberculosis (TB), and CD4+ T cell immunity is the main target of current TB vaccine c

223 Adaptive CD8 T-cell immunity is the principal arm of the cellular alloi

224 cell antigen presentation, but its role in T-cell immunity is unknown.

225 T cell immunity is vital for the control of KSHV infection

226 kine pathway is critical in shaping CD8(+) T cell immunity, locally within latently infected tissues,

227 standing of how the existing DMTs modulate B-cell immunity may identify future targets for therapeuti

228 but it is unknown whether disturbances to T cell immunity may render these patients vulnerable to fu

229 T-cell immunity might be an essential component of safe, e

230 he notable implication that restoring CD4+ T cell immunity might contribute to controlling HCV infect

231 hanced dengue infections suggest that poor T-cell immunity might have contributed to protection failu

232 of whether preexisting dengue virus (DENV) T cell immunity modulates these responses.

233 cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of grea

234 , we evaluated the contributions to CD8(+) T cell immunity of CD40 expressed on host tissues includin

235 e a dual impact of host adaptive antitumor T-cell immunity on the clinical effectiveness of rapalogs

236 ve generally focused on either stimulating T cell immunity or driving antibody-directed effector func

237 ction, pDCs can also process Ag and induce T cell immunity or tolerance.

238 s study, we sought to investigate the role T cell immunity plays in recognizing and controlling genet

239 Naturally occurring cross-protective T-cell immunity protects against symptomatic PCR-confirmed

240 identifies a IRE1alpha-XBP1-cMyc axis in NK cell immunity, providing insight into host protection ag

241 PO-R signaling on T cells to inhibition of T-cell immunity, providing one mechanism that could explai

242 e molecular mechanisms of vaccine-elicited T cell immunity remains a critical knowledge gap in vaccin

243 irectly affect cancer immune phenotype and T cell immunity remains a standing question.

244 dritic cells (DCs) in priming WNV-specific T cell immunity remains poorly understood.

245 However, the influence of SOR on T cell immunity remains uncharacterized.

246 tumor defenses and recover the preexisting T-cell immunity required to respond to immunotherapy.

247 T-cell immunity requires extremely rapid clonal proliferat

248 rases that have evolved to escape the host's cell immunity response following virus infection.

249 Absent T-cell immunity resulting in life-threatening infections p

250 Mouse studies of T cell immunity show that, in response to infection, T cel

251 f B cells in TB vaccine-induced protective T cell immunity still remains unknown.

252 parameters of M. tuberculosis-specific CD4 T cell immunity that are impaired in HIV-infected individu

253 ut elicited a systemic Foxp3(+) CD25(+) Treg cell immunity that suppressed diabetes induction by a su

254 Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint bl

255 the importance of the co-receptor PD-1 in T cell immunity, the upstream signaling pathway that regul

256 urther demonstrate that, unlike evasion of T cell immunity, this viral Fcgamma receptor is not requir

257 ecruitment of mast cells and activation of T cell immunity through C3a are important for parasite con

258 novel insights into how viruses can evade NK cell immunity through the selection of mutations in HLA-

259 nse, these observations support a role for T cell immunity to AhpC in disease protection.

260 allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin.

261 Thus, long-term CD8(+) T cell immunity to chronic viral infection requires unique

262 us (CMV) persists in most humans, requires T cell immunity to control, yet tissue immune responses re

263 T cell immunity to GroEL (BPSL2697) was specifically impai

264 Studies of T-cell immunity to human cytomegalovirus (CMV) primarily r

265 pitope recognition by CD8(+)T cells, CD4(+)T cell immunity to KSHV may be important for maintaining t

266 culosis infection, and in the evolution of T-cell immunity to M. tuberculosis in response to tubercul

267 eptor 3 (CXCR3) chemokine pathway promotes T cell immunity to many viral pathogens, but its importanc

268 l neoantigens as the basis for ineffective T cell immunity to melanoma and support the concept that t

269 for p110delta signaling in in vivo CD8(+) T cell immunity to microbial pathogens.

270 Survival was associated with enhanced T cell immunity to nine of fifteen immunodominant antigens

271 dogenous NK cell and tumor Ag-specific CD8 T cell immunity to provide a marked reduction in tumor bur

272 al pathogens, but its importance in CD8(+) T cell immunity to recurrent herpes has been poorly elucid

273 es that better recapitulate natural CD8(+) T cell immunity to SARS-CoV-2.

274 Preexisting T cell immunity to severe acute respiratory syndrome coron

275 modifying therapies (DMTs) for MS modulate B-cell immunity to some degree.

276 stance may provide insight into protective T cell immunity to TB.

277 (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the

278 ines are a promising approach for inducing T cell immunity to tumor neoantigens.

279 th an imbalance of T(H)1 versus regulatory T cell immunity toward the retinal protein, recoverin.

280 nhances the human NoV-specific mucosal and T cell immunities triggered by a VSV-based human NoV vacci

281 metabolic regulator controlling antitumor T cell immunity, underscoring the potential of creatine su

282 hocytes, are critical for the induction of B cell immunity upon viral infection.

283 associated with more pronounced antitumor T-cell immunity via induction of IL17 and IFNgamma-produci

284 ain-containing molecule 4 (Tim4) regulates T-cell immunity via phagocytosis of both apoptotic (high P

285 on; and (iv) inhibiting antitumor adaptive T cell immunity via the programmed death-1 (PD-1)-programm

286 Reconstitution of CMV-specific T cell immunity was evident and CMV-specific ACT may trigg

287 ficient and wild-type neutrophils, whereas T cell immunity was increased in chimeric mice with NGAL-d

288 LRs) and B cell receptors (BCRs) in the TI B cell immunity, we here used MyD88-, TRIF-, and alpha-gal

289 enetic diagnosis nor basic measurements of T-cell immunity were good predictors of disease evolution.

290 successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic dr

291 Trib1) as a central regulator of antiviral T cell immunity, where loss of Trib1 led to a sustained en

292 endritic cells (DCs) is required to induce T cell immunity, whereas immature DCs can induce immune to

293 ccine development have focused on adaptive T cell immunity, whereas the importance of innate immune c

294 tial for the initiation of adaptive CD8(+) T cell immunity, which in turn is critical for effective c

295 onverge on NFATc1 with opposing effects on T cell immunity, which may underlie the beneficial effect

296 ic CD4(+) T-cell compartment that suppress T-cell immunity while concomitantly promoting aberrant IgG

297 of which is necessary for preservation of T cell immunity while suppressing tissue damage.

298 ide criteria for optimizing protective CD8 T cell immunity with rAd vaccines.

299 ioning regulates the extent and quality of T cell immunity, with important implications for vaccine d

300 These results imply an ongoing beta cell immunity years after onset of diabetes and suggest